The European Society of Cardiology (ESC) published Guidelines on cardiomyopathies on 25 August 2023 in European Heart Journal. [1] This is the first international guideline document to include all cardiomyopathy subtypes, and the first time that specific recommendations are made for cardiomyopathies other than hypertrophic cardiomyopathy.
ESC Congress 2023 Intravascular imaging-guided percutaneous coronary intervention (PCI) is associated with a lower rate of target lesion failure compared with angiography-guided PCI, according to research presented at the ESC Congress 2023.
ESC Congress 2023 Pulsed field ablation (PFA) is as effective and safe as conventional thermal ablation for the treatment of paroxysmal atrial fibrillation (AF), according to research presented at ESC Congress 2023.
ESC Congress 2023 Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial infarction survivors with heart failure still an adequate therapy for prevention of sudden cardiac death? The PROFID EHRA trial is set to answer this question in a large, multicentre, EU-funded study. The consortium of partners and colleagues involved in the […]
ESC Congress 2023 Active screening of patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD) more than doubles new diagnoses of cardiovascular disease compared with usual care, according to research presented at ESC Congress 2023.
Study reports on switch to newer anticoagulants in frail elderly with atrial fibrillation
The European Society of Cardiology held their annual congress in Amsterdam from 25-28 August 2023. There were more than 30,000 participants and 4,500 faculty and presenters. International Hospital presents a selection of highlights from what was a very busy event.
Newly engineered CRISPR enzyme for editing DNA is more compact yet just as efficient as current Cas9 tool, and could improve patient treatment.
Researchers from the University of Eastern Finland teamed up with industry and supercomputers to carry out one of the world’s largest virtual drug screens. By doing so they managed to boost virtual screening with machine learning enabling a 10-fold time reduction in the processing of 1.56 billion drug-like molecules.
Scientists at the Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, USA, have developed a sophisticated device with multiple capabilities to effectively treat deep, non-compressible, and irregularly-shaped wounds. In their recent publication in Advanced Science [1], they describe a groundbreaking device that addresses rapid haemorrhage management, minimizes inflammatory effects, and ensures infection control. Additionally, the […]
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
